WO2012061015A3 - Supplémentation en l-citrulline au cours d'une thérapie de déplétion d'arginine par l'arginase - Google Patents

Supplémentation en l-citrulline au cours d'une thérapie de déplétion d'arginine par l'arginase Download PDF

Info

Publication number
WO2012061015A3
WO2012061015A3 PCT/US2011/056831 US2011056831W WO2012061015A3 WO 2012061015 A3 WO2012061015 A3 WO 2012061015A3 US 2011056831 W US2011056831 W US 2011056831W WO 2012061015 A3 WO2012061015 A3 WO 2012061015A3
Authority
WO
WIPO (PCT)
Prior art keywords
arginase
arginine depletion
depletion therapy
supplementation during
citrulline
Prior art date
Application number
PCT/US2011/056831
Other languages
English (en)
Other versions
WO2012061015A2 (fr
Inventor
Arthur E. Frankel
Jeremy P. Mauldin
Jung Hee Woo
Original Assignee
Scott & White Healthcare
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scott & White Healthcare filed Critical Scott & White Healthcare
Publication of WO2012061015A2 publication Critical patent/WO2012061015A2/fr
Publication of WO2012061015A3 publication Critical patent/WO2012061015A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des procédés et des compositions pour la réduction de la toxicité d'un agent anticancéreux qui met en jeu la citrulline ou un analogue de celle-ci. Des exemples non limitants d'agents anticancéreux comprennent des agents de déplétion de l'arginine.
PCT/US2011/056831 2010-11-03 2011-10-19 Supplémentation en l-citrulline au cours d'une thérapie de déplétion d'arginine par l'arginase WO2012061015A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40979510P 2010-11-03 2010-11-03
US61/409,795 2010-11-03

Publications (2)

Publication Number Publication Date
WO2012061015A2 WO2012061015A2 (fr) 2012-05-10
WO2012061015A3 true WO2012061015A3 (fr) 2012-08-23

Family

ID=46025001

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/056831 WO2012061015A2 (fr) 2010-11-03 2011-10-19 Supplémentation en l-citrulline au cours d'une thérapie de déplétion d'arginine par l'arginase

Country Status (1)

Country Link
WO (1) WO2012061015A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012085793A1 (fr) * 2010-12-21 2012-06-28 Ning Man Cheng Utilisation d'arginase humaine recombinante pégylée pour le traitement d'une leucémie
GB2568000A (en) 2016-08-08 2019-05-01 Aerase Inc Compositions and methods for treating cancer with arginine depletion and immuno oncology agents
WO2019113157A1 (fr) 2017-12-05 2019-06-13 Aerase, Inc. Procédé et composition pour le traitement d'une déficience en arginase 1
CN114729344A (zh) * 2019-08-30 2022-07-08 安格利亚生物制药公司 人重组精氨酸酶1的生产方法及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050024361A (ko) * 2002-06-20 2005-03-10 바이오-캔서 트리트먼트 인터내셔널 리미티드 아르기닌 결핍에 의한 인간 악성 종양의 치료제 및 치료방법
WO2010023195A2 (fr) * 2008-08-26 2010-03-04 Kyon Biotech Ag Compositions et procédés pour le traitement du cancer
US20100111925A1 (en) * 2008-10-31 2010-05-06 The Board Of Regents Of The University Of Texas System Compositions of Engineered Human Arginases and Methods for Treating Cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050024361A (ko) * 2002-06-20 2005-03-10 바이오-캔서 트리트먼트 인터내셔널 리미티드 아르기닌 결핍에 의한 인간 악성 종양의 치료제 및 치료방법
WO2010023195A2 (fr) * 2008-08-26 2010-03-04 Kyon Biotech Ag Compositions et procédés pour le traitement du cancer
US20100111925A1 (en) * 2008-10-31 2010-05-06 The Board Of Regents Of The University Of Texas System Compositions of Engineered Human Arginases and Methods for Treating Cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BANSAL, V. ET AL.: "Citrulline can preserve proliferation and the loss of CD3 ? chain under conditions of low arginine.", JOURNAL OF PARENTERAL AND ENTERAL NUTRITION., vol. 28, no. 6, 2004, pages 423 - 430 *

Also Published As

Publication number Publication date
WO2012061015A2 (fr) 2012-05-10

Similar Documents

Publication Publication Date Title
EP3452597A4 (fr) Procédés et compositions d'agents biologiquement actifs
IL232515A0 (en) nadph 4 oxidase inhibitors and pharmaceutical preparations containing them
IL222548A (en) Hydroxamic acid derivatives and their antimicrobial and antimicrobial preparations
BR112015011830A2 (pt) compostos e seus métodos de utilização
HK1201044A1 (en) Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof tlr2
EP2877159B8 (fr) Compositions inhibitrices d'écoulement et méthodes de traitement à l'aide celles-ci
EP4324527A3 (fr) Formulations d'enzalutamide
IL228984A0 (en) Preparations and methods for stabilization of active agents
IL223889B (en) Contrasting side effects associated with the administration of an anti-hyaluronan factor and methods for alleviating or preventing the side effects
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
IN2014DN10670A (fr)
WO2012058241A3 (fr) Procédés et compositions pour amélioration du cancer du pancréas
MX344324B (es) Endoprotesis que contiene un recubrimiento de substancia activa.
EP2608800A4 (fr) Compositions et utilisations de substances présentant une forte activité antimicrobienne et une faible toxicité
IN2014DN07483A (fr)
EP3291835A4 (fr) Sous-ensemble de cellules nkt pour la persistance et l'activité thérapeutiquein vivo
WO2012073047A3 (fr) Compositions et procédés
WO2012104240A3 (fr) Utilisation cosmétique
PH12014500859A1 (en) Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
EP2723345A4 (fr) Composition contenant de la phosphatidylcholine en tant que principe actif et destinée à atténuer la toxicité d'agents anticancéreux
EP2794879A4 (fr) Compositions et procédés pour l'administration d'arn biologiquement actifs
HRP20170987T1 (hr) Fibrinolitički pripravci koji sadrže bromelain i natokinazu za sprječavanje i liječenje flebotrombotičkih stanja
HK1203395A1 (en) Implantable devices and methods for the evaluation of active agent
WO2012061015A3 (fr) Supplémentation en l-citrulline au cours d'une thérapie de déplétion d'arginine par l'arginase
WO2013019093A3 (fr) Nouveaux dérivés de l'aniline et leur utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11838449

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11838449

Country of ref document: EP

Kind code of ref document: A2